Colostrum Proteins in Protection against Therapy-Induced Injuries in Cancer Chemo- and Radiotherapy: A Comprehensive Review.
Jolanta ArtymMichał ZimeckiPublished in: Biomedicines (2023)
In this article, we review the benefits of application of colostrum and colostrum-derived proteins in animal models and clinical trials that include chemotherapy with antimetabolic drugs, radiotherapy and surgical interventions. A majority of the reported investigations was performed with bovine colostrum (BC) and native bovine or recombinant human lactoferrin (LF), applied alone, in nutraceutics or in combination with probiotics. Apart from reducing side effects of the applied therapeutics, radiation and surgical procedures, BC and LF augmented their efficacy and improved the wellness of patients. In conclusion, colostrum and colostrum proteins, preferably administered with probiotic bacteria, are highly recommended for inclusion to therapeutic protocols in cancer chemo- and radiotherapy as well as during the surgical treatment of cancer patients.
Keyphrases
- human milk
- locally advanced
- recombinant human
- early stage
- papillary thyroid
- clinical trial
- rectal cancer
- radiation therapy
- low birth weight
- radiation induced
- end stage renal disease
- squamous cell carcinoma
- photodynamic therapy
- ejection fraction
- squamous cell
- cancer therapy
- newly diagnosed
- chronic kidney disease
- prognostic factors
- young adults
- combination therapy
- physical activity
- lymph node metastasis
- drug delivery
- preterm infants
- high glucose
- diabetic rats
- childhood cancer
- oxidative stress
- endothelial cells
- preterm birth
- stress induced